FDA semi-annual agenda
This article was originally published in The Rose Sheet
Oral care products that claim to reduce or prevent dental plaque and gingivitis are expected to be addressed by a notice of proposed rulemaking in May 2007, while timetables for final actions related to skin-bleaching products containing hydroquinone and the prohibition of certain cattle material in human food and cosmetics have yet to be determined, according to FDA's semi-annual agenda, which appeared in the Dec. 11 Federal Register. The agency had targeted December 2006 for a notice of proposed rulemaking on UVA/UVB sunscreens, having postponed the measure previously (1"The Rose Sheet" May 23, 2005, In Brief). An advance notice of proposed rulemaking for combination sunscreen-and-insect-repellant OTC products was also slated for release last month...
You may also be interested in...
In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.